Please select the option that best describes you:
What systemic therapy would you offer to a patient with metastatic EGFR exon 19 deleted NSCLC to the brain with isolated CNS progression while on osimertinib 80 mg and progressed through WBRT?
Do you consider dose escalating to 160 mg or do you add chemotherapy to osimertinib?
Answer from: Medical Oncologist at Academic Institution
If this is isolated CNS progression, the answer will depend on the number of metastatic sites. This is worth a conversation with your radiation oncologist. If there are 1-5 sites progressing within the CNS, it may be reasonable to consider treating these with SRS (even if patients have had prior who...
Sign in or Register to read more